Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eliapixant DDI with Rosuvastatin in Healthy Participants
NCT04252300Phase 1Completed
- Sponsor
- Bayer
- Start
- Mar 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of eliapixant in chronic cough and pain, sponsored by Bayer. Primary endpoints: Maximum plasma concentration of rosuvastatin without concomitant administration of BAY1817080 at Day 5, Maximum plasma concentration of rosuvastatin after concomitant administration of BAY1817080 at Day 15 and 2 more. Started Mar 2020; status: completed.
02
Drugs
eliapixant
03
Conditions
chronic coughpain
Beyond the preview
Go deeper on NCT04252300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04252300.